Infants are the most vulnerable population at risk for serious diseases. Respiratory syncytial virus (RSV) is a disease that can be detrimental in infants because of their immature lungs and immune system. Palivizumab, a humanized monoclonal antibody medication, given every 28-30 days has been shown to reduces RSV symptoms and decrease rates of hospitalization by 15%. By reducing the rate of hospital stay, it will also reduce cost.
Date of publication
MSN Capstone Project
MSN in Education
Hang, William, "Decreasing Hospitalization in Infants" (2020). MSN Capstone Projects. Paper 32.